olaparib

olaparib is a targeted cancer therapy belonging to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. It is primarily used in the treatment of certain ovarian, breast, pancreatic, and prostate cancers that harbor specific genetic mutations, most notably in the BRCA1 and BRCA2 genes. Developed by the pharmaceutical company AstraZeneca, it was the first PARP inhibitor approved by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency, marking a significant advancement in precision medicine.

Medical uses

Olaparib is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and have a BRCA mutation. It is also approved for the treatment of patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously been treated with chemotherapy. Furthermore, approvals extend to the maintenance treatment of pancreatic adenocarcinoma with a germline BRCA mutation and for certain patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations. Its use is contingent upon companion diagnostic tests to confirm the presence of relevant genetic alterations.

Adverse effects

Common adverse effects include nausea, fatigue, anemia, vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, cough, arthralgia, rash, and abdominal pain. More serious but less frequent risks include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and pneumonitis. Hematological toxicities such as neutropenia, thrombocytopenia, and lymphopenia are also monitored. Patients are advised to report signs of infection or unusual bleeding, and regular monitoring of complete blood counts is recommended throughout treatment.

Pharmacology

As a PARP inhibitor, olaparib exerts its pharmacological effect by inhibiting the activity of the PARP-1, PARP-2, and PARP-3 enzymes, which are involved in DNA repair, particularly the repair of single-strand breaks. In cancer cells with deficient homologous recombination repair (HRR), such as those with BRCA1/2 mutations, inhibition of PARP leads to an accumulation of DNA damage and cell death through the mechanism of synthetic lethality. It is administered orally and is metabolized primarily in the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP3A5.

History

The development of olaparib originated from collaborative research between scientists at Cancer Research UK, the University of Cambridge, and KuDOS Pharmaceuticals, a biotechnology company later acquired by AstraZeneca. The concept of targeting PARP in BRCA-deficient cancers was pioneered by researchers including Professor Nicola Curtin and teams led by Professor Alan Ashworth. Following promising early-phase clinical trials, olaparib received its first regulatory approval from the European Medicines Agency in 2014 for advanced BRCA-mutated ovarian cancer. The U.S. Food and Drug Administration granted accelerated approval later that same year, with subsequent approvals expanding its indications based on pivotal trials such as SOLO-1, OlympiAD, and POLO.

Society and culture

Marketed under the brand name Lynparza, olaparib is a high-cost therapy that has sparked discussions about drug pricing and access within healthcare systems like the National Health Service (NHS) in the United Kingdom. Its development is often cited as a landmark success story for the UK life sciences sector and for the application of basic research in DNA repair biology to clinical medicine. The drug has been the subject of significant media coverage, highlighting patient stories and the paradigm of personalized cancer treatment. Its approval has also influenced the design of numerous subsequent clinical trials investigating PARP inhibitors in other cancer types and combinations.

Category:Antineoplastic drugs Category:PARP inhibitors Category:AstraZeneca